Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat -: Effect mediated through central or enteric nervous mechanisms

被引:104
作者
Tolessa, T
Gutniak, M
Holst, JJ
Efendic, S
Hellström, PM [1 ]
机构
[1] Karolinska Hosp, Karolinska Inst, Dept Med, Gastroenterol Sect, SE-17176 Stockholm, Sweden
[2] Karolinska Hosp, Karolinska Inst, Dept Endocrinol & Metab, SE-17176 Stockholm, Sweden
[3] Univ Copenhagen, Panum Inst, Dept Physiol, DK-2200 Copenhagen, Denmark
关键词
gastric emptying; gastrointestinal motility; glucagon-like peptide-1; rat; small intestine; smooth muscle;
D O I
10.1023/A:1026678925120
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
This study investigated effects of glucagon-like peptide-1 (7-36)amide (GLP-1) on gastric emptying, small intestinal transit, and contractility of smooth muscle strips in rats. GLP-1 at doses of 10 and 20 pmol/kg/min administered intravenously dose-dependently retarded transit of the small intestine (P < 0.001), while only the higher dose of 20 pmol/kg/min retarded gastric emptying (P < 0.01). GLP-1 at concentrations up to 10(-4) M did not affect the basal tone or contractility of the gastrointestinal muscle strips that were stimulated with electric field stimulation or acetylcholine. Our results demonstrate that small intestinal transit seems more sensitive than gastric emptying to inhibition by GLP-1 at physiologic levels in plasma. Furthermore, this inhibition appears to be mediated through central mechanisms rather than through peripheral actions. Thus, GLP-1 is suggested to inhibit gastric emptying and small intestinal transit through an indirect effect via central or enteric nervous mechanisms.
引用
收藏
页码:2284 / 2290
页数:7
相关论文
共 37 条
[1]  
Brown J C, 1975, Recent Prog Horm Res, V31, P487
[2]  
BUENO L, 1977, AM J PHYSIOL, V230, pG1538
[3]  
CRYER PE, 1993, HYPOGLYCAEMIA DIABET, P275
[4]   EFFECTS OF GLUCAGON-LIKE PEPTIDE I-(7-36) ON RELEASE OF INSULIN, GLUCAGON, AND SOMATOSTATIN BY RAT PANCREATIC-ISLET CELL MONOLAYER-CULTURES [J].
DALESSIO, DA ;
FUJIMOTO, WY ;
ENSINCK, JW .
DIABETES, 1989, 38 (12) :1534-1538
[5]   DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].
DEACON, CF ;
JOHNSEN, AH ;
HOLST, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957
[6]   GLUCAGON-LIKE PEPTIDE-I ANALOGS - EFFECTS ON INSULIN-SECRETION AND ADENOSINE-3',5'-MONOPHOSPHATE FORMATION [J].
GEFEL, D ;
HENDRICK, GK ;
MOJSOV, S ;
HABENER, J ;
WEIR, GC .
ENDOCRINOLOGY, 1990, 126 (04) :2164-2168
[7]  
GIRALT M, 1996, NEUROGASTROENT MOTIL, V8, pA173
[8]   Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas [J].
Gutniak, MK ;
Guenifi, A ;
Berggren, LJ ;
Holst, JJ ;
Hellstrom, PM ;
Efendic, S .
DIABETES CARE, 1996, 19 (08) :857-863
[9]   EFFECTS OF NEUROTENSIN ON THE TRANSIT OF GASTROINTESTINAL CONTENTS IN THE RAT [J].
HELLSTROM, PM ;
NYLANDER, G ;
ROSELL, S .
ACTA PHYSIOLOGICA SCANDINAVICA, 1982, 115 (02) :239-243
[10]  
HELLSTROM PM, 1989, J GASTROINTEST MOTIL, V1, P35